TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01204697
Drug: erlotinib [Tarceva]
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150 mg/day orally, days 2-16 each 3-week cycle for 4 cycles; 150 mg/day orally thereafter
Study: NCT01204697
Drug: erlotinib [Tarceva]
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150 mg/day orally as monotherapy
Study: NCT04048655
Drug: Neostigmine, Combinations
Normalized name: neostigmine, combinations
DrugBank: Neostigmine (DB01400)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients have neostigmine induced recovery of neuromuscular block.
Study: NCT01682577
Drug: Perindopril 4 mg tablets of PT Dexa Medica
DrugBank: Perindopril (DB00790)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Test product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
Study: NCT01682577
Drug: Perindopril 4 mg tablets of Servier
DrugBank: Perindopril (DB00790)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reference product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
Study: NCT02373241
Drug: Losartan
Normalized name: Losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard dosing
Study: NCT02373241
Drug: Losartan
Normalized name: Losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Experimental dosing
Study: NCT01707329
Drug: Icotinib+chemotherapy
Normalized name: Nicotine
DrugBank: Icotinib (DB11737)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Icotinib: 125 mg is administered orally three times per day. Chemotherapy: docetaxel 75mg/m2, 4 cycles; or pemetrexed 500mg/m2, 4 cycles.
Study: NCT01174953
Drug: finasteride
Normalized name: Finasteride
DrugBank: Finasteride (DB01216)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Finasteride 5 mg once daily~Soy 4 capsules twice daily (160 mg total)
Study: NCT03104855
Drug: d6-25-hydroxyvitamin D3
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous administration of stable isotope-labeled D6-25(OH)D3
Study: NCT02192398
Drug: Guanfacine
Normalized name: Guanfacine
DrugBank: Guanfacine (DB01018)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will be randomized into 1 of the following 3 treatment groups:~1. guanfacine (2mg)~2. guanfacine (1mg)~3. placebo~To compare pain threshold, pain tolerance, and wind up, as measured by QST, throughout 4 weeks of drug treatment (guanfacine or placebo).
Study: NCT00457483
Drug: hydrochlorothiazide
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12.5 mg once-a-day
Study: NCT00457483
Drug: valsartan, 80 mg once-a-day
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 80 mg once-a-day
Study: NCT00664755
Drug: varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Day -7 thru -5: 0.5mg QD Day -4 thru -1: 0.5mg BID Day 0 onward: 1.0mg BID~Varenicline is taken for a duration of 4 weeks in this study.
Study: NCT00104078
Drug: MYO-029
Normalized name: MYO-029
DrugBank: Stamulumab (DB05915)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04094766
Drug: Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of CAR-T cells. After a pre-treatment lymphodepletion therapy, patients will receive the Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy by intravenous injection.
Study: NCT03982186
Drug: JNJ-73763989
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-73763989 will be administered as medium dose (Arms 1 and 3), high dose (Arm 2), and low dose (Arm 4) as subcutaneous injection.
Study: NCT03714919
Drug: Dextromethorphan
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative oral dextromethorphan 1 mg/kg
Study: NCT03714919
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intraoperative intravenous dexmedetomidine 0.5 μg/kg
Study: NCT03982186
Drug: JNJ-56136379
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-56136379 tablets will be administered orally.
Study: NCT03714919
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative intravenous ketamine 0.5 mg/kg
Study: NCT02287402
Drug: AO-128
Normalized name: monofluorophosphate
DrugBank: Monofluorophosphate ion (DB02348)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AO-128 tablet
Study: NCT04247815
Drug: ATI-450
Normalized name: ATI-355
DrugBank: ATI-355 (DB17923)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, small molecule MK2 inhibitor
Study: NCT02593110
Drug: Telmisartan
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants randomized to the telmisartan arm of the study will take 20 mg or 40 mg of telmisartan daily based on the results of their study run-in. Participants will have their dose increased to up to 80 mg as tolerated.
Study: NCT01447043
Drug: Ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients with wet AMD treated with ranibizumab as prescribed by physician
Study: NCT00253721
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All levels: Every 4 weeks for up to one year~Dose Escalation Plan:~Level 1: 4mg/m2/day x 2 days~Level 2: 6mg/m2/day x 2 days~Level 3: 8mg/m2/day x 2 days~Level 4: 10mg/m2/day x 2 days~Level 5: 12mg/m2/day x 2 days
Study: NCT00791895
Drug: biphasic insulin aspart 30
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treat-to-target dose titration scheme
Study: NCT02171780
Drug: BI 1744 CL
Normalized name: hydroxypropyl bis-hydroxyethyldimonium chloride
DrugBank: Propyl acetate (DB01670)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04646876
Drug: Magnesium Sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prospective , comparative , double blind study
Study: NCT01168752
Drug: Debio 0932
Normalized name: DEBIO-1347
DrugBank: DEBIO-1347 (DB12903)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelatin capsules of 2 dosage strengths (25 mg or 100 mg) The maximum dose will depend on the number of dose levels necessary to determine the MTD.~In both schedules the study treatment will be continued, until one of the study treatment discontinuation criteria is met.
Study: NCT00256399
Drug: Alfuzosin 10 mg
Normalized name: alfuzosin 10 mg oral tablet, extended release
DrugBank: Alfuzosin (DB00346)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00251745
Drug: Dexlansoprazole MR
Normalized name: Dexlansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dexlansoprazole MR 60 mg, capsules, orally, once daily for 4 weeks.
Study: NCT00251745
Drug: Dexlansoprazole MR
Normalized name: Dexlansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dexlansoprazole MR 90 mg, capsules, orally, once daily for 4 weeks.
Study: NCT04202380
Drug: Ampicillin
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients will receive Ampicillin 2gm IV every 6 hours for 2 days
Study: NCT01301729
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg/m2 iv every 3 weeks, 6 cycles (18 weeks)
Study: NCT01301729
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 90 mg/kg iv (+/-10%) every 3 weeks for 6 3-week cycles (18 weeks)
Study: NCT01301729
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 4 mg/kg iv loading dose on Day 1, 2 mg/kg iv on Day 8 and weekly thereafter
Study: NCT03071276
Drug: Selinexor
Normalized name: Selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given orally on days 1,3,8,10,22 and 24 of each cycle
Study: NCT03071276
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Will be given intravenously (IV) over 30 minutes daily on days 16 through 20. Fludarabine may be given prior to day 16 if it is determined to be in the participant's best interest based on disease progression. Chemotherapy may be delayed by 1-3 days if clinically indicated.
Study: NCT03071276
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Will be given IV over 4 hours daily on days 16 through 20. Cytarabine may be given prior to day 16 if it is determined to be in the participant's best interest based on disease progression. Chemotherapy may be delayed by 1-3 days if clinically indicated.
Study: NCT02796053
Drug: TAB08
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The TAB08 will be administered intravenously, by infusion.
Study: NCT00426439
Drug: Chloroquine
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine tablets gives as 50 mg/kg divided into 6 doses giver twice a day for 3 days.
Study: NCT03123068
Drug: CocoaVia®
DrugBank: Cocoa (DB10977)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CocoaVia® is manufactured by Mars, Inc. It is a dietary supplement of cocoa bean extract, containing 125 mg cocoa flavanols per capsule.
Study: NCT00265369
Drug: Spores of Bacillus Clausii Probiotic Strain
Normalized name: Bacillus clausii
DrugBank: Bacillus clausii (DB16537)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01748929
Drug: Albendazole
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04429516
Drug: Morphine Sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: over-encapsulated Morphine Sulfate prolonged release 5mg tablet, twice daily for 14 days. Patients will then crossover after a 7 day wash out period.
Study: NCT04137042
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative fluid therapy is administrated by using 0.9% saline
Study: NCT01911273
Drug: PF-03446962
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF 03446962 7 mg/kg, IV, every 2 weeks, until disease progression, patient refusal or unacceptable toxicity, whichever occurs first
Study: NCT00262665
Drug: ORG 24448
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: flexible regimen starting at 250mg once a day, increasing to maximum of 750mg twice a day.
Study: NCT00004263
Drug: 7-hydroxystaurosporine (UCN-01)
Normalized name: 7-Hydroxystaurosporine
DrugBank: 7-Hydroxystaurosporine (DB01933)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/m2 IV over 24 hours on days 2-4 of course 1 and over 36 hours beginning on day 2 of subsequent courses. Treatment repeats every 4 weeks for a maximum of 4 courses.
Study: NCT00004263
Drug: Cytarabine (Ara-C)
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Starting dose 1 g/m2 IV over 24 hours on days 1-4 of each course. Treatment repeats every 4 weeks for a maximum of 4 courses.
Study: NCT02216097
Drug: PF-04457845
Normalized name: PF-04457845
DrugBank: PF-04457845 (DB12012)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4mg PF-04457845 tablet taken once daily for 7 days.
Study: NCT02500602
Drug: doxazosin
Normalized name: Doxazosin
DrugBank: Doxazosin (DB00590)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: active medication
Study: NCT02445599
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5 mg Dormicum intramuscularly, administered 1 hour before surgery
Study: NCT02445599
Drug: Atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5 mg Atropine intramuscularly, administered 1 hour before surgery
Study: NCT02790853
Drug: Proflavine Hemisulfate
Normalized name: Proflavine hemisulfate
DrugBank: Proflavine (DB01123)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Applied on mucosa
Study: NCT03009045
Drug: Tedizolid
Normalized name: Tedizolid
DrugBank: Tedizolid phosphate (DB09042)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200mg oral tedizolid one pill per day
Study: NCT02445599
Drug: Nalbuphine
Normalized name: Nalbuphine
DrugBank: Nalbuphine (DB00844)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1st choice for rescue analgetic 10-20 mg intravenously
Study: NCT02445599
Drug: Metamizole-sodium
Normalized name: metamizole sodium
DrugBank: Metamizole (DB04817)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional rescue analgetic 2g intravenously
Study: NCT02445599
Drug: Tramadol
Normalized name: Tramadol
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Additional rescue analgetic 100mg intravenously
Study: NCT04011124
Drug: Fluzoparib
Normalized name: Fluzoparib
DrugBank: Fluzoparib (DB15637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose on Day 1 and Day 12
Study: NCT04011124
Drug: Rifampicin
Normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: QD on Day 5-14 for 10 days
Study: NCT03161340
Drug: Rapamycin
Normalized name: Rapamycin
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will take Rapamycin 2 days before IVF until 15 days after IVF
Study: NCT02350816
Drug: HGT-1410
Normalized name: HGTV-43
DrugBank: HGTV-43 (DB05807)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HGT-1410 administered according to Patient Group assignment.
Study: NCT04493567
Drug: BMS-986036
Normalized name: BMS-986036
DrugBank: Pegbelfermin (DB15365)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT01453179
Drug: Imiquimod
Normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: One course of treatment (COT) consisting of an overnight application of IMIQ (1 sachet for up to 50 cm2), applied 3 nights per week (e.g. Monday, Wednesday, Friday) for 4 weeks followed by a 4 weeks treatment pause. If necessary, this may be followed by a second COT.
Study: NCT03172494
Drug: Insulin degludec/liraglutide
Normalized name: INSULIN DEGLUDEC/LIRAGLUTIDE
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneously (s.c., under the skin)administration once daily in combination with metformin.~For 26 weeks.
Study: NCT03172494
Drug: Insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneously (s.c., under the skin)administration once daily in combination with metformin.~For 26 weeks.
Study: NCT03172494
Drug: Liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneously (s.c., under the skin)administration once daily in combination with metformin.~For 26 weeks.
Study: NCT03939663
Drug: misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: misoprostol 2 tablets
Study: NCT02764151
Drug: PF-06840003
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily Oral PF-06840003
Study: NCT00797589
Drug: HES
Normalized name: HES
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20ml/kg as prime fluid
Study: NCT00281957
Drug: sorafenib tosylate
Normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT00281957
Drug: tipifarnib
Normalized name: Tipifarnib
DrugBank: Tipifarnib (DB04960)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally
Study: NCT00281957
Drug: temsirolimus
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT02523300
Drug: saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The other 120 patients will be given saline as control group
Study: NCT00773474
Drug: Lonafarnib
Normalized name: LONAFARNIB
DrugBank: Lonafarnib (DB06448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All registered patients will be treated with Lonafarnib 200 mg PO BID daily on days 1-21 of every 21-day cycle until progression of disease, unacceptable toxicity, or investigator's discretion.
Study: NCT00226980
Drug: Thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00732485
Drug: fenofibrate
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fenofibrate, PO, 5 mg/kg/day from admission to 6 months post burn
Study: NCT00451178
Drug: enzastaurin
Normalized name: Enzastaurin
DrugBank: Enzastaurin (DB06486)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1125 milligrams (mg) then 500 mg, oral, daily, six 21-day cycles or up to 3 years
Study: NCT00451178
Drug: rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375 milligrams per square meter (mg/m\^2), intravenous (IV), Day 1 every 21 days, six 21-day cycles
Study: NCT00451178
Drug: vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.4 mg/m\^2, IV, Day 1 every 21 days, six 21-day cycles
Study: NCT00451178
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg, oral, Days 1-5, six 21-day cycles
Study: NCT01428154
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single 1.5 μg/kg subcutaneous (SC) dose administration on day 1
Study: NCT03440125
Drug: Cayenne Pepper topical
Normalized name: Cayenne pepper
DrugBank: Red pepper (DB14759)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20min topical Cayenne Pepper Cataplasm application containing 5% Cayenne Pepper nd 95% Kaolin mixed with water
Study: NCT02267044
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The drug used for the interscalene blocks
Study: NCT03106389
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 micro grams misoprostol administered vaginally followed every 6 hours by 400 micro grams orally until complete expulsion
Study: NCT00122759
Drug: ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01843738
Drug: Vemurafenib
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The starting dose of vemurafenib will be the patient's baseline tolerating dose, between 720 - and 960 mg PO bid.
Study: NCT03452137
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab intravenous infusion will be administered at a fixed dose on Day 1 of each 21-day cycle for 16 cycles.
Study: NCT00004126
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00004126
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01080560
Drug: Cyclosporine Capsules USP (Modified) 100 mg
Normalized name: cyclosporine Oral Capsule
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be administered either Test Product or Reference Product with 240ml of water according to randomization schedule
Study: NCT02657928
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT02657928
Drug: Ribociclib
Normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT04898101
Drug: Acalabrutinib
Normalized name: Acalabrutinib
DrugBank: Acalabrutinib (DB11703)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants in Cohort 1 will receive a single 100 mg oral capsule dose of acalabrutinib on Day 1.
Study: NCT04458285
Drug: Sacubitril / Valsartan Oral Tablet [Entresto]
Normalized name: sacubitril / valsartan Oral Tablet [Entresto]
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients in experimental group will receive sacubitril/valsartan with the recommended starting dose: 50mg twice daily (if previous ACEI, ensure 36-hour washout period), after 2-4 weeks, the dose will be doubled to the target maintenance dose of 100mg twice daily(if tolerated) for 12 weeks.
Study: NCT04458285
Drug: Valsartan 80mg Tablet
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients in active comparator group will receive Valsartan with an dose of 80 mg once daily.
Study: NCT02232386
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ibrutinib (PCI-32765) 420 mg (3 x 140 mg capsules) will be administered orally once daily. The first dose will be delivered in the clinic on Day 1, after which subsequent dosing is typically on an outpatient basis.
Study: NCT02232386
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab 375 mg/m2 iv. Month 1: day 1 of weeks 1, 2, 3, 4; months 2-6: day 1of week 1.
Study: NCT03632915
Drug: Levetiracetam
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Standard of care
Study: NCT03632915
Drug: Lacosamide
Normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Standard of care
Study: NCT03632915
Drug: Phenobarbital
Normalized name: Phenobarbital
DrugBank: Phenobarbital (DB01174)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care
Study: NCT03632915
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard of care
Study: NCT03632915
Drug: Valproic Acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard of care